ClinicalTrials.gg
Not yet recruitingNCT07570355Updated May 6, 2026

Pterygopalatine Ganglion Stimulation for the Treatment of Geographic Atrophy

An interventional study of Pterygopalatine ganglion stimulation and Sham pterygopalatine ganglion stimulation in Geographic Atrophy, sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian. Not yet recruiting at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the feasibility and safety of pterygopalatine ganglion (PPG) stimulation in adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

The main questions it aims to answer are:

Is PPG stimulation feasible to implement, as reflected by participant adherence to the intervention and completion of follow-up assessments? Is PPG stimulation safe, as assessed by the incidence of adverse events and clinical ophthalmic examinations? What are the preliminary effects of PPG stimulation on choroidal perfusion, retinal sensitivity, visual acuity, and the progression of GA lesion area?

Researchers will compare active PPG stimulation with sham stimulation (a procedure that mimics the intervention without delivering real stimulation) to assess feasibility and safety, while exploring potential therapeutic effects.

Participants will:

Receive active or sham PPG stimulation according to randomization over a 12-month study period Attend scheduled clinic visits for safety monitoring and multimodal ophthalmic assessments Undergo examinations including optical coherence tomography (OCT), fundus autofluorescence imaging, microperimetry, and visual acuity testing

02

Conditions studied

  • Geographic Atrophy

Keywords

  • Geographic Atrophy
  • Pterygopalatine Ganglion
  • Sphenopalatine Ganglion
  • Clinical Trial
  • Age-related Macular Degeneration
03

In context

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

This study's planned enrollment of 62 is below the median of 70 across 141 interventional studies indexed under Geographic Atrophy.

Browse Geographic Atrophy studies →

Lead sponsor

Shanghai Institute of Acupuncture, Moxibustion and Meridian is the lead sponsor of 29 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Best-corrected visual acuity (BCVA), as measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, ranging from 25 to 80 letters (Snellen equivalent, 20/320 to 20/25).
  • A confirmed diagnosis of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), with no involvement of the foveal center. Fundus autofluorescence (FAF) imaging must demonstrate a total GA area of 2.5 to 17.5 mm² located within a 30° field centered on the fovea, with the presence of any pattern of increased autofluorescence at the junctional zone of GA. In cases of multifocal GA, at least one lesion must be ≥1.25 mm² in size.

    • If both eyes meet the eligibility criteria, the eye with the worse BCVA will be selected as the study eye. If BCVA is equal in both eyes, the right eye will be designated as the study eye.

Exclusion criteria

Exclusion Criteria:

  • History or evidence of submacular surgery or other treatments for AMD in the study eye, with the exception of oral vitamin and mineral supplementation.
  • History of intraocular surgery within 3 months prior to screening, or the presence of ocular conditions requiring surgical intervention during the study period.
  • Receipt of any periocular or intravitreal injection therapy in the study eye within 3 months prior to screening.
  • History or evidence of choroidal neovascularization in either eye, or the presence of any other retinal disease that may confound the assessment of macular structure or function (e.g., diabetic retinopathy or pathologic myopia).
  • Presence of severe systemic disease or any other condition deemed unsuitable for study participation.
  • Inability to comply with scheduled visits or complete study procedures due to cognitive impairment or other factors, as judged by the investigator.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Active stimulation

    Procedure: Pterygopalatine ganglion stimulation

  • Sham comparator
    Sham stimulation

    Procedure: Sham pterygopalatine ganglion stimulation

Interventions

  • ProcedurePterygopalatine ganglion stimulation

    Electrical stimulation was delivered using a disposable sterile needle electrode (0.30 × 60 mm; Beijing Keyuan Medical Devices Co., Ltd., China). Under ultrasound guidance, the needle tip was advanced into the pterygopalatine fossa. Ipsilateral pterygopalatine ganglion stimulation was administered to the study eye using an intermittent waveform at a frequency of 5 Hz and a current intensity of 1-2 mA for 10 minutes. The stimulation intensity was adjusted to elicit a mild local electrical sensation as perceived by the participant.

    Also known as: Sphenopalatine ganglion stimulation

  • ProcedureSham pterygopalatine ganglion stimulation

    During sham stimulation, a disposable stainless steel needle (0.25 × 25 mm) was inserted superficially at the same anatomical location as in the active stimulation group, to a depth of approximately 2 cm. Ultrasound guidance was applied in an identical manner to that used in the active intervention to mimic the procedural experience. However, the internal circuitry of the stimulation device was disconnected to prevent current delivery. The device interface continued to display real-time parameters, including current intensity, frequency, and stimulation duration, thereby maintaining the appearance of active operation.

    Also known as: Sham sphenopalatine ganglion stimulation

06

What researchers measure

Primary outcomes

  1. Proportion of participants who completed the trial

    Proportion of participants who were successfully randomized to either intervention group, fully adhered to the assigned intervention protocol, and completed all scheduled follow-up assessments.

    Time frame: At 12 months

Secondary outcomes

  1. Incidence of adverse events

    Time frame: From enrollment to 12 months

  2. Choroidal structure

    Time frame: -7 to 0 days, 1, 3, 6, 9, and 12 months

  3. Retinal sensitivity

    Time frame: Baseline (0), 6 months, and 12 months

  4. Standard and low-luminance best corrected visual acuity

    Time frame: -7 to 0 days, 1, 3, 6, 9, and 12 months

  5. Geographic atrophy lesion area and square root-transformed geographic atrophy area

    Time frame: -7 to 0 days, 6 months, and 12 months

  6. Contrast sensitivity

    Time frame: Baseline (0), 1, 3, 6, 9, and 12 months

  7. 25-item National Eye Institute Visual Function Questionnaire score

    Vision-related quality of life was assessed using the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25). This corresponds to a score between 0 and 100, with higher scores indicating better visual quality of life

    Time frame: Baseline (0), 6 months, and 12 months

  8. Treatment credibility scale score

    Assessed by asking participants to rate their response to five questions on a 10-point treatment credibility scale developed by Borkovec and Nau. Higher scores represent higher expectations of efficacy.

    Time frame: 1 week and 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jun 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
May 6, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Jun 1, 2028
CompletionEst.
Jul 31, 2028
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07570355
Lead sponsor
Shanghai Institute of Acupuncture, Moxibustion and Meridian
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Jun 1, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
May 6, 2026

Study contacts

Xiehe Kong, MD
Contact
ynomrahkong@163.com
021-13621775647

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion